Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Genetics Institute/Johns Hopkins

This article was originally published in The Gray Sheet

Executive Summary

Genetics Institute/Johns Hopkins: Form Metamorphix, Inc. to develop and commercialize transforming growth factor-beta (TGF~) genes, which are involved in cell growth and differentiation. GI, a unit of American Home Products, will contribute $3.6 mil. in exchange for 58% of the new company. GI is conducting pilot clinical trials on one type of TGF~ gene it discovered, bone morphogenic proteins, for treating tibia and maxillofacial bone fractures, and for use in spinal reconstruction. The latter trial is part of a four-year, $50 mil. collaboration with Sofamor Danek announced earlier this year ("The Gray Sheet" Feb. 20, I&W-2)...

You may also be interested in...



EU Approvals: Evenity Cleared For Severe Osteoporosis

The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.

 

IGBA Urges WIPO To Revoke Patent Database Support

The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.

AAM Criticizes Lower Health Care Costs Act

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

UsernamePublicRestriction

Register

MT004059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel